Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

Key Points
Hims & Hers Health stock beat on earnings but suffered a steep sales slowdown in Q4.
Hims & Hers is trying to figure out how to grow without selling GLP-1 drugs.
Down 70% over the past year -- and down 60% over just the last three months -- Hims & Hers Health (NYSE: HIMS) stock is in a funk, and Monday night's earnings report didn't help.
Shares of the telemedicine company have slid steadily since the FDA announced early last year that Novo Nordisk's (NYSE: NVO) Wegovy and Ozempic GLP-1 weight loss drugs are no longer in shortage. Since that news came out, the writing has seemed to be on the wall for Hims & Hers Health and its business of compounding copycat weight loss drugs for direct sale to patients.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Throw in a bit of price competition from branded manufacturers of GLP-1 drugs, Novo Nordisk and Eli Lilly (NYSE: LLY), who have cut prices as much as 80%, and Hims' growth slowed significantly in the fourth quarter of 2025.
Hims & Hers 2025 earnings
Hims & Hers reported its earnings for Q4 and all of 2025 Monday night. The company "beat earnings," with quarterly profit of $0.08 per share but missed slightly on sales, reporting $617.8 million. (Wall Street wanted to see $618.7 million.)
Sales for the quarter grew 28%, which sounds like a lot -- but relative to a full-year sales growth rate of 59%, it appears quarterly growth got cut in half. What's more, the slowdown may be spilling into 2026. While on the one hand, Hims insists it will beat forecasts for the year, generating about $2.8 billion in sales, management said its Q1 2026 sales will come in between $600 million and $625 million -- missing analyst forecasts of $654 million.
Investors were underwhelmed by the report, selling off Hims' stock by more than 8% Monday night. Given there are also worries the FDA may ban Hims & Hers from continuing to sell GLP-1 compounds, it's understandable investors are nervous.
But here's the thing: While selling copycat Ozempic is a big part of Hims & Hers Health's business, it's far from the only thing this healthcare stock does.
Hims & Hers & not just GLP-1 copycats
In its 10-K filing accompanying the earnings report, Hims & Hers confirmed it grew sales 59% in 2025, from $1.5 billion to $2.3 billion. 40% of sales came from the company's Hers brand, and GLP-1 sales drove the growth at Hers. But even so, "The majority of our total United States Revenue came from non-GLP-1 offerings."
In a postearnings conference call investor relations head Bill Newby went so far as to say that "the vast majority of the revenue is made from the non-GLP-1 business" and "we expect that trend to continue."
What does this mean for investors? Management's being coy about exactly how much of its sales come from copycat Ozempic. Whatever the number is, however, management seems confident it can still do $2.8 billion in sales this year, even without much help from GLP-1 sales. But the more sales Hims got from GLP-1s last year, which may disappear this year, the more impressive the growth rate would have to be to still hit $2.8 billion.
Despite the GLP-1 fiasco, Hims & Hers stock is growing like a weed. The younger you are as an investor, the longer you'll have to profit from this growth.
Should you buy stock in Hims & Hers Health right now?
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $420,864!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,182,210!*
Now, it’s worth noting Stock Advisor’s total average return is 903% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 26, 2026.
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore

Novo Nordisk (NYSE:NVO), which develops and markets diabetes and obesity treatments, closed Wednesday at $38.16, down 1.11%. The stock slipped as investors weighed a large Vivtex partnership while watching how competition and margins shape Novo’s obesity and diabetes franchise. Trading volume reached 54.7 million shares, about 141% above its three-month average of 22.7 million shares. Novo Nordisk IPO'd in 1981 and has grown 23,750% since going public.
How the markets moved today
The S&P 500 added 0.82% to finish Wednesday at 6,947, while the Nasdaq Composite gained 1.26% to close at 23,152. Within pharmaceuticals, industry peers showed mixed action as Eli Lilly closed at $1,028.83, down 1.28%, while Novartis ended at $166.85, off 0.16%.
What this means for investors
It has been a rough week for Novo Nordisk as its shares have dropped 20% over the last five business days. On Monday, the stock declined roughly 15% after its next-gen obesity medicine CagriSema reported less weight loss than Eli Lilly’s new drug in a similar Phase 3 trial, tempering sales expectations. Then on Tuesday, Novo Nordisk announced it would cut prices for Wegovy and Ozempic by 35% to 50% in the U.S. on Jan. 1, 2027.
These two news items prompted JPMorgan and Kepler Capital Markets to downgrade NVO stock. Today, the company signed a $2.1 billion partnership with Vivtex to develop higher-bioavailability biologics, which could help it fight back against Eli Lilly. I like the deal, and at 11 times earnings, Novo is an intriguing value stock to consider.
Should you buy stock in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $420,864!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,182,210!*
Now, it’s worth noting Stock Advisor’s total average return is 903% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 25, 2026.
JPMorgan Chase is an advertising partner of Motley Fool Money. Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies

Key Points
Eli Lilly and Novo Nordisk are leaders in the GLP-1 market.
This class of drugs has been in high demand among people aiming to shed pounds.
One of the biggest growth markets in the pharmaceutical industry today is that of weight loss drugs. Novo Nordisk got the ball rolling when it launched Ozempic back in 2017. The drug, part of the GLP-1 class, was approved for type 2 diabetes but also proved to be useful for weight loss. Novo Nordisk followed up by winning approval for the same ingredient -- semaglutide -- under the name Wegovy for weight loss.
Eli Lilly (NYSE: LLY) soon joined with tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound for obesity. Though Novo led the market in the early days, Lilly soon gained ground -- and slipped ahead. Today, Lilly holds a 60% share of the U.S. market for these kinds of drugs.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
And now Lilly just took two major steps forward in this billion-dollar market. Here's what you need to know.
How GLP-1 drugs work
Let's start with a few quick notes on GLP-1 drugs and Lilly's path along this road so far. GLP-1 drugs soared to popularity with the release of Ozempic as doctors and patients realized their weight-loss potential. These drugs act on hormonal pathways involved in digestion, so they help in the key areas of appetite and blood sugar control.
Today's drugs come in injectable format, administered on a weekly basis. The one exception is the recently approved Wegovy pill -- and regulators are reviewing Lilly's oral weight loss candidate, orforglipron, right now, so a second pill option may be on the horizon.
Novo held the first-to-market advantage, but in recent years, Lilly's drugs have taken the lead. One reason for this may be due to efficacy. In a head-to-head trial, for example, Zepbound helped patients lose more weight than Wegovy. All of this has resulted in soaring revenue and stock performance for Lilly.
Now, let's turn to the latest pieces of news that could push this company further ahead. Novo's CagriSema, a GLP-1 and amylin analogue combo that's currently under regulatory review, didn't beat Lilly's Zepbound in a phase 3 trial. CagriSema -- in a dose of 2.4 mg of cagrilintide and 2.4 mg of semaglutide -- delivered weight loss of 23% over 84 weeks. That's compared to weight loss of more than 25% for 15 mg dosage of tirzepatide.
A positive sign for Lilly
CagriSema, which acts on additional pathways involved in weight control, has been seen as a potential product to rival the Lilly drug -- so this latest trial result isn't good news for Novo. But it is positive for Lilly, as it adds to evidence that Zepbound may be the most effective drug available.
The second piece of news isn't related to efficacy, but it is related to something else that's important to patients: convenience. Lilly just released a new Zepbound format that holds a month's worth of doses in a single pen. This could make treatment easier for patients while they're traveling, for example, as they don't have to carry around as many devices. Mounjaro already is available in this format, called the KwikPen.
This latest news, reinforcing the efficacy and convenience of Zepbound, clearly should work in Lilly's favor in the quarters to come. It's important to remember that this market is growing too, with analysts expecting it to reach nearly $100 billion over the coming four years. And Lilly's orforglipron and farther down the road, other potential drugs could add to growth as this story unfolds.
Facing competition
Of course, Lilly likely will face increasing competition in the coming years. Novo remains a significant player, and other potential market participants -- from Pfizer to Viking Therapeutics -- could take some market share. These companies and others are studying weight loss candidates in clinical trials right now.
Lilly could lose momentum if a rival enters the market with a stronger product. So far, though, Lilly's current products and its pipeline, as well as its massive investments in manufacturing, show its ambition in this market. And that means it has a solid chance of staying ahead and delivering long-term growth to investors.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $420,864!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,182,210!*
Now, it’s worth noting Stock Advisor’s total average return is 903% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 25, 2026.
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know.

Key Points
The big news around Novo Nordisk for the past couple of years has been about GLP-1 drugs.
Looking back in its history, however, the longer-term story is about its role in treating diabetes.
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are locked in a battle around GLP-1 weight-loss drugs. It is a huge potential market, and the new class of drugs is very important. However, Novo Nordisk's story is much bigger than weight loss. Here's why it could be a long-term hold no matter what happens in the market, or with GLP-1 drugs.
Novo Nordisk made insulin before GLP-1 drugs
Novo Nordisk is one of the world's largest producers of insulin, a vital medication for those with diabetes. Generally speaking, when you take insulin, you need it regularly. As such, Novo Nordisk has a very attractive recurring revenue stream. That's an important foundation for the business.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
One area where this pharmaceutical company's foundation shows up is in its dividend payout ratio. Despite falling behind Eli Lilly in the GLP-1 weight-loss drug space, Novo Nordisk's trailing 12-month payout ratio is a very comfortable 40%. In fact, it has never risen above 50%, even during the deep 2007 to 2009 recession.
Meanwhile, the dividend yield is well above the market at 3.9%. For reference, the average pharmaceutical stock has a yield of 1.7%. So the high yield here is well supported, and that's largely thanks to the company's strong diabetes business.
GLP-1 drugs are important, too
That said, investors shouldn't ignore that Novo Nordisk is also a GLP-1 drug stock. Eli Lilly has taken the lead, but Novo Nordisk remains an important player in the new drug niche. Notably, it recently launched the first GLP-1 pill, which should help it regain market share from Eli Lilly, at least in the short term. People prefer pills over shots, for obvious reasons.
The takeaway from Novo Nordisk's development of a GLP-1 pill is that it remains an innovative drug maker. The excitement around weight-loss drugs is so high that investors may be overlooking the company's long-term opportunities and fundamental business strengths. All Wall Street is seeing is the fact that Eli Lilly's GLP-1 drugs are performing better in the market right now.
Novo Nordisk's strong core business and ongoing innovation in a newly developing drug niche suggest this financially strong dividend stock is an attractive holding, no matter what the market is doing. Indeed, consumers are still going to need insulin during a bear market and people will probably still be looking to lose weight, too.
Should you buy stock in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $420,864!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,182,210!*
Now, it’s worth noting Stock Advisor’s total average return is 903% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 25, 2026.
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash

The NASDAQ 100 Pre-Market Indicator is up 102.62 to 25,079.66. The total Pre-Market volume is currently 159,892,801 shares traded.
The following are the most active stocks for the pre-market session:
Circle Internet Group, Inc. (CRCL) is +11.24 at $72.61, with 4,323,122 shares traded. CRCL's current last sale is 74.86% of the target price of $97.
Novo Nordisk A/S (NVO) is -0.79 at $37.80, with 3,182,829 shares traded., following a 52-week high recorded in prior regular session.
Joby Aviation, Inc. (JOBY) is +0.5903 at $10.31, with 2,096,957 shares traded. JOBY's current last sale is 103.1% of the target price of $10.
Lithium Americas Corp. (LAC) is +0.3828 at $5.42, with 888,465 shares traded. LAC's current last sale is 83.43% of the target price of $6.5.
LATAM Airlines Group S.A. (LTM) is unchanged at $58.01, with 871,688 shares traded. As reported by Zacks, the current mean recommendation for LTM is in the "buy range".
Southwest Airlines Company (LUV) is +0.25 at $50.89, with 725,737 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2026. The consensus EPS forecast is $0.51. LUV's current last sale is 94.24% of the target price of $54.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-Market Most Active for Feb 25, 2026 : CRCL, NVO, JOBY, LAC, LTM, LUV

(RTTNews) - Danish drugmaker Novo Nordisk and biotechnology company Vivtex Corp. announced Wednesday a partnership to develop next-generation oral biologic medicines for obesity, diabetes and associated comorbidities.
Vivtex is a pre-clinical drug development company that launched as a MIT spin off based on a proprietary platform developed in the laboratories of biotech legend Robert Langer in 2018.
Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk, while Vivtex is eligible to receive upfront consideration, research funding and milestone payments totalling up to 2.1 billion US dollars, and tiered royalties on future product sales.
The collaboration aims to enable the oral delivery of biologic drug candidates that are traditionally limited to injectable administration due to poor absorption in the gastrointestinal tract.
The partnership combines Novo Nordisk's deep expertise in peptide and protein therapeutics with Vivtex's proprietary gastrointestinal screening and formulation platform to identify next-generation oral therapeutics.
Vivtex's platform combines multiple proprietary gastrointestinal screening assays, drug-delivery technologies, and computational simulation and AI capabilities to optimize the oral delivery of biologic medicines. Novo Nordisk will assume responsibility for global development, regulatory activities, manufacturing, and commercialization of any resulting products.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Novo Nordisk Partners Vivtex To Develop Next-generation Oral Medicines For Obesity And Diabetes

Key Points
Turning $100,000 into $1 million is a task few stocks can accomplish.
Novo Nordisk doesn't seem likely to do so, especially given the challenges it is facing.
The stock could still be a buy at current levels.
Novo Nordisk's (NYSE: NVO) shares have lagged the market over the past couple of years. However, the Denmark-based pharmaceutical specialist remains one of the undisputed leaders in the GLP-1 drug market. And analysts predict this niche will grow at a good clip over the next decade.
Could Novo Nordisk ride the GLP-1 wave in the next 10 years and turn $100,000 into $1 million along the way?
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
What would it take?
Novo Nordisk should be at the forefront of the GLP-1 boom over the next 10 years. The company's semaglutide, marketed under brands such as Wegovy, Ozempic, and Rybelsus, is one of the best-selling GLP-1 therapies. Novo Nordisk also has several pipeline candidates in this niche that should receive approval soon.
But even assuming near-perfect execution -- and granting that this market will reach the heights Wall Street expects -- the GLP-1 gold rush over the next decade is highly unlikely to lead to the kinds of returns needed to turn $100,000 into $1 million -- that's a 25.89% compound annual growth rate, something very few companies can achieve over long periods, even if they are performing well.
What's more, Novo Nordisk isn't exactly in the best of shape right now. It has been losing ground in the GLP-1 space to its biggest competitor, Eli Lilly. And even its next-gen weight loss medicine, CagriSema, failed to prove as effective in a phase 3 study when pitted against Eli Lilly's Zepbound, so the latter should keep its lead intact. Novo Nordisk's revenue will decline on a year-over-year basis in 2026, based on the company's projections.
The pharmaceutical leader could bounce back. It has a deep pipeline, the cash to pursue shrewd licensing deals and acquisitions to bolster it, and proven expertise in developing GLP-1 products. And although CagriSema did not match Zepbound, it still showed strong weight-loss results. Even so, more competition will likely mean less clinical differentiation and lower pricing power for the company -- something that will limit its upside. So, it's not realistic to expect Novo Nordisk to achieve the $100,000 to $1 million goal (or anything close) in the next decade.
Is the stock a buy?
Novo Nordisk has been a leader in the diabetes drug market for decades. The company is likely to remain so, and that's an area where there is still plenty of work to be done.
Novo Nordisk has also been looking to diversify its lineup, something it should gradually succeed in over the next five to 10 years. The stock might be struggling right now, but after the beating it took in recent years, it might be worth investing in, given its leadership in diabetes and weight loss and its deep pipeline. And for investors willing to hold the stock for a long time, the dividend can help boost returns over the decade and beyond.
Should you buy stock in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $409,970!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,174,241!*
Now, it’s worth noting Stock Advisor’s total average return is 889% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 25, 2026.
Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush?

Key Points
A rival just cut the price of a competing medication.
This puts the list price of weight-loss drug Zepbound under pressure.
A price war for weight-loss drugs is intensifying, and it's clear Eli Lilly (NYSE: LLY) investors weren't happy about it. On news that the company's arch-rival in the category had cut prices for several of its medications, those folks sold out of Eli Lilly stock to push it to a nearly 2% loss on Tuesday.
Slimming down
That rival is Danish pharmaceutical company Novo Nordisk, best-known for its Wegovy obesity treatment that directly competes with Eli Lilly's Zepbound. Early Tuesday morning, Novo Nordisk announced a set of price cuts to its leading products, including Wegovy.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
The European company said that the list price for the medication -- in addition to that of its sibling drug indicated for diabetes, Ozempic, and related diabetes drug Rybelsus -- would be cut to $675 for a one-month supply. That represents quite a chop, as all three treatments are currently listed at over $1,000. Novo Nordisk said the changes would take effect on Jan. 1, 2027.
Similarly, Zepbound's list price at present is more than $1,000 per monthly supply.
No reason to panic
Understandably, investors fear that this latest (and rather aggressive) pricing move will put a serious dent in Eli Lilly's revenue. That'll happen in the weight-loss segment for sure; however, we have to keep this in perspective -- the company is massive and sprawling, with both commercialized and developmental products in many therapeutic areas. Its fortunes are therefore not dependent on how the drug is selling.
That said, Zepbound is quite the contributor to Eli Lilly's overall revenue. Its sales more than doubled year over year in the fourth quarter of 2025 to nearly $4.3 billion, accounting for 22% of the company's total top line.
So yes, Zepbound matters for the company, but a reduced sale price won't make Eli Lilly stock a sell. I feel this company's equity is still worth owning, given the size of both its commercial and developmental portfolios.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $409,970!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,174,241!*
Now, it’s worth noting Stock Advisor’s total average return is 889% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 24, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Why Eli Lilly Stock Slumped Today

(RTTNews) - Novo Nordisk A/S (NVO), along with The United Laboratories International Holdings Limited, Tuesday announced topline results from a Chinese phase 2 trial of UBT251, a drug jointly developed by both companies for the treatment of obesity.
The trial investigated the safety and efficacy of once-weekly injectable 2 mg, 4 mg and 6 mg doses of UBT251 compared to placebo in Chinese people.
The findings showed that starting from a baseline mean body weight of 92.2 kg, the highest mean weight loss observed for people treated with UBT251 was 19.7 percent compared to 2.0 percent in the placebo group after 24 weeks of treatment.
Additionally, all dose groups of UBT251 showed statistically significant improvements relative to placebo on key secondary endpoints, including waist circumference, blood glucose, blood pressure and lipids.
United Biotechnology will present detailed data from the Chinese phase 2 trial at a medical congress later this year. Based on these findings, the company plans to initiate a phase 3 trial in Chinese patients.
Meanwhile, Novo Nordisk has initiated a global phase 1b/2a trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of different doses of UBT251 for up to 28 weeks in around 330 people, with topline data expected in 2027.
Also, it plans to initiate a phase 2 trial with UBT251 in people with type 2 diabetes in the second half of 2026.
Currently, NVO is moving down 2.46 percent, to $38.65 on the New York Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Novo Nordisk, United Laboratories International Announce Positive Topline Data From UBT251 Trial

(RTTNews) - Novo Nordisk A/S (NVO) announced Tuesday that it will lower the list price or wholesale acquisition cost (WAC), Wegovy (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, and Rybelsus (semaglutide) tablets 7 mg or 14 mg to $675, effective January 1, 2027.
This represents price reduction of approximately 50% and 35% for Wegovy and Ozempic, respectively, from the current list price. Wegovy, Ozempic, and Rybelsus deliver powerful efficacy in addition to offering a broad range of indications unlike other GLP-1s.
The price cut will help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States. It will also address access barriers to these innovative medicines, especially for patients whose out-of-pocket costs are linked to list price.
These changes in list price do not have an impact on direct-to-patient, self-pay prices.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Novo Nordisk A/S

Options Strategies